Investors should monitor Q2 2026 for updated prostate cancer data and initiation of the NSCLC phase 3 trial, and Q4 2026 for BLA submission and linoserpaturev survival data. The reduced net loss was largely non-operational (warrant revaluation), so focus should remain on clinical execution and upcoming catalysts.
Price Chart
Executive Summary
Candel Therapeutics reported Q4 and full-year 2025 financial results, highlighting a significant increase in R&D and operating expenses, though full-year net loss decreased year-over-year due to favorable changes in warrant liability valuation. The company strengthened its balance sheet with $50M drawn from a $130M term loan and $93.5M in net proceeds from a February 2026 equity offering, positioning it to fund operations into Q1 2028. Key upcoming catalysts include a planned BLA submission for aglatimagene in prostate cancer in Q4 2026 and initiation of a pivotal phase 3 trial in NSCLC in Q2 2026.
Key Financial Metrics
Key Facts
- Net loss for Q4 2025 was $29.5M vs $14.1M in Q4 2024; full-year net loss was $38.2M vs $55.2M in 2024 due to $10.1M net other income from warrant liability revaluation.
- R&D expenses increased to $30.5M in 2025 from $19.3M in 2024, driven by aglatimagene program costs.
- Cash and cash equivalents were $119.7M as of December 31, 2025; combined with $93.5M net proceeds from a February 2026 equity offering, funding extends into Q1 2028.
- Entered a $130M term loan facility with Trinity Capital, with $50M drawn at closing and up to $80M in future tranches.
- Plans to submit BLA for aglatimagene in prostate cancer in Q4 2026 and initiate pivotal phase 3 trial in NSCLC in Q2 2026.
- IND cleared for linoserpaturev in rHGG; mature OS data expected in Q4 2026.
- Royalty funding agreement with RTW Investments for up to $100M contingent on FDA approval in prostate cancer.
Financial Impact
Cash runway extended into Q1 2028 via $50M debt drawdown and $93.5M equity raise; $100M potential royalty financing tied to approval. R&D spend up 58% YoY to $30.5M.
Risk Factors
- High cash burn: R&D and G&A expenses are rising rapidly, and future funding may require additional dilution or debt.
- Clinical trial delays or negative data in prostate or NSCLC programs could derail BLA plans and commercial timelines.
- BLA submission and approval are not guaranteed, despite Fast Track and RMAT designations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254591 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $10.16 | awaiting T+60 | — | $8.27 (−18.60%) |
Sep 30, 2026 27d ago | Press Release | $10.44 | awaiting T+60 | — | $8.27 (−20.79%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.27 (−27.01%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.27 (−27.01%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $8.27 (−31.99%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $8.27 (−29.92%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $8.27 (−29.92%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $8.27 (−17.87%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.27 (−15.87%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.27 (−15.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers